Platform Strategy For Improving Manufacturability And Efficacy In Bispecific Antibodies

By Wooseok Yang, PhD, Director of Platform Technology Evaluation; Kihong Kim, Director of Ab Platform Discovery, Samsung Biologics

Bispecific antibodies offer significant therapeutic advantages by simultaneously engaging two biological targets, enabling novel mechanisms for treating complex diseases such as cancer. However, their structural complexity introduces substantial development and manufacturing challenges, including chain mispairing, product heterogeneity, purification difficulties, and the need to maintain critical quality attributes without compromising biological activity. Advances in antibody engineering are addressing these obstacles by incorporating developability considerations directly into molecular design. By promoting correct heavy- and light-chain assembly at the earliest stages of molecule formation, these strategies improve product purity, expression, stability, and manufacturing consistency while reducing downstream purification burden. Analytical characterization demonstrates that these design improvements can achieve high yields, favorable stability, and robust manufacturability without diminishing target binding or therapeutic function. Functional studies further show effective modulation of disease-associated signaling pathways, inhibition of tumor cell proliferation, and sustained antitumor activity in preclinical models, confirming that enhanced manufacturability need not come at the expense of efficacy.

Collectively, these findings highlight the importance of integrating molecular engineering with process development to streamline the production of increasingly complex biologics. As bispecific and multispecific antibody formats continue to expand across therapeutic applications, engineering approaches that simultaneously optimize developability and biological performance will play an increasingly important role in enabling scalable manufacturing, accelerating development timelines, and improving access to next-generation targeted therapies.